paclitaxel + radium-223 dichloride

Paclitaxel + radium-223 dichloride is an investigational combination therapy being studied primarily for the treatment of advanced cancers with bone metastases, such as metastatic breast cancer. Paclitaxel is a chemotherapeutic agent that inhibits cell division by stabilizing microtubules, thereby preventing mitosis and inducing apoptosis in rapidly dividing tumor cells. Radium-223 dichloride is a radiopharmaceutical that mimics calcium and selectively targets areas of increased bone turnover, such as sites of bone metastases. It emits alpha particles that cause double-stranded DNA breaks in nearby tumor cells, leading to localized cytotoxicity with minimal impact on surrounding healthy tissue. The rationale for combining these agents is to leverage the systemic antitumor effects of paclitaxel with the targeted radiotherapeutic action of radium-223 dichloride against bone lesions[1][2][3].

Brand names

Xofigo

Other names

radium-223 dichloride + paclitaxel